Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits

Ladan Zand, S Vincent Rajkumar, Nelson Leung, Sanjeev Sethi, Mireille El Ters, Fernando C Fervenza, Ladan Zand, S Vincent Rajkumar, Nelson Leung, Sanjeev Sethi, Mireille El Ters, Fernando C Fervenza

Abstract

Background: Treatment of proliferative GN with monoclonal Ig deposits (PGNMID) is not established. A monoclonal anti-CD38 antibody (daratumumab) is effective in treating multiple myeloma. Abnormal plasma cell clones may play a role in the pathogenesis of PGNMID.

Methods: We evaluated daratumumab's safety and efficacy in an open-label, phase 2 trial in 11 adults with PGNMID and one with C3 glomerulopathy (C3G) with monoclonal gammopathy. Patients had an eGFR >20 ml/min per 1.73 m2 and proteinuria >1 g/d. They received daratumumab intravenously (16 mg/kg) once weekly for 8 weeks, and then every other week for eight additional doses. Primary outcome was safety, defined as major infections, grade 3 or 4 anemia, leukopenia, or thrombocytopenia. Secondary outcomes were rate of complete remission (proteinuria <500 mg/d with <15% decline in baseline eGFR) or partial remission (>50% reduction in 24-hour proteinuria with <30% decline in eGFR) and proteinuria at 6 and 12 months.

Results: One patient with C3G had GN unrelated to the monoclonal gammopathy, and one with PGNMID did not complete the first infusion. Five serious adverse events occurred. During the 12 months of the trial, six of the ten patients with PGNMID who received at least one dose of daratumumab had a partial response, and four had a complete response (an overall response rate of 100%). Three patients experienced relapse, two of whom re-entered partial remission after resuming daratumumab therapy. Proteinuria declined significantly, from a median of 4346 mg/d to 1264 mg/d by 12 months.

Conclusions: Daratumumab demonstrated an acceptable safety profile and resulted in significant improvement in proteinuria while stabilizing kidney function in patients with PGNMID, suggesting the drug merits further investigation.

Clinical trial registry name and registration number: Daratumumab in Treatment of PGNMID and C3 GN, NCT03095118.

Keywords: daratumumab; glomerulonephritis; monoclonal; proliferative.

Copyright © 2021 by the American Society of Nephrology.

Figures

Graphical abstract
Graphical abstract
Figure 1.
Figure 1.
Flow chart of the study including number of patients assessed for primary and secondary outcome.
Figure 2.
Figure 2.
Proteinuria response from baseline and at 6 and 12 months in patients who received at least one dose of daratumumab.

References

    1. Merlini G, Stone MJ: Dangerous small B-cell clones. Blood 108: 2520–2530, 2006.
    1. Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP, et al. .; International Kidney and Monoclonal Gammopathy Research Group: Monoclonal gammopathy of renal significance: When MGUS is no longer undetermined or insignificant. Blood 120: 4292–4295, 2012.
    1. Nasr SH, Satoskar A, Markowitz GS, Valeri AM, Appel GB, Stokes MB, et al. .: Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol 20: 2055–2064, 2009.
    1. Sethi S, Zand L, Leung N, Smith RJ, Jevremonic D, Herrmann SS, et al. .: Membranoproliferative glomerulonephritis secondary to monoclonal gammopathy. Clin J Am Soc Nephrol 5: 770–782, 2010.
    1. Bhutani G, Nasr SH, Said SM, Sethi S, Fervenza FC, Morice WG, et al. .: Hematologic characteristics of proliferative glomerulonephritides with nonorganized monoclonal immunoglobulin deposits. Mayo Clin Proc 90: 587–596, 2015.
    1. Bridoux F, Desport E, Frémeaux-Bacchi V, Chong CF, Gombert JM, Lacombe C, et al. .: Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: A fortuitous association? Clin J Am Soc Nephrol 6: 2165–2174, 2011.
    1. Zand L, Kattah A, Fervenza FC, Smith RJ, Nasr SH, Zhang Y, et al. .: C3 glomerulonephritis associated with monoclonal gammopathy: A case series. Am J Kidney Dis 62: 506–514, 2013.
    1. Sethi S, Sukov WR, Zhang Y, Fervenza FC, Lager DJ, Miller DV, et al. .: Dense deposit disease associated with monoclonal gammopathy of undetermined significance. Am J Kidney Dis 56: 977–982, 2010.
    1. Ravindran A, Fervenza FC, Smith RJH, Sethi S: C3 glomerulopathy associated with monoclonal Ig is a distinct subtype. Kidney Int 94: 178–186, 2018.
    1. Gumber R, Cohen JB, Palmer MB, Kobrin SM, Vogl DT, Wasserstein AG, et al. .: A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits. Kidney Int 94: 199–205, 2018.
    1. Chauvet S, Frémeaux-Bacchi V, Petitprez F, Karras A, Daniel L, Burtey S, et al. .: Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. Blood 129: 1437–1447, 2017.
    1. Guiard E, Karras A, Plaisier E, Duong Van Huyen JP, Fakhouri F, Rougier JP, et al. .: Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: Correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol 6: 1609–1616, 2011.
    1. Lepori N, Cheungpasitporn W, Sethi S, Murray D, Kumar S, Leung N, Giridhar KV, Fervenza FC: High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathy. Clin Nephrol 89: 291–299, 2018.
    1. Said SM, Cosio FG, Valeri AM, Leung N, Sethi S, Salameh H, et al. .: Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft. Kidney Int 94: 159–169, 2018.
    1. Sethi S, Fervenza FC, Rajkumar SV: Spectrum of manifestations of monoclonal gammopathy-associated renal lesions. Curr Opin Nephrol Hypertens 25: 127–137, 2016.
    1. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. .: Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): An open-label, randomised, phase 2 trial. Lancet 387: 1551–1560, 2016.
    1. Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, et al. .: Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373: 1207–1219, 2015.
    1. Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. .; POLLUX Investigators: Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375: 1319–1331, 2016.
    1. Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. .; CASTOR Investigators: Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375: 754–766, 2016.
    1. Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. .; MAIA Trial Investigators: Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 380: 2104–2115, 2019.
    1. National Institutes of Health, National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE). Version 5. Bethesda, MD, National Institutes of Health National Cancer Institute, 2017.
    1. Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. .: Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128: 384–394, 2016.
    1. Turner M: Molecules Which Recognize Antigen. In: Immunology, edited by Roitt IM, Brostoff J, Male DK, Mosby CV, London, Gower Medical Publishing, 1989, pp 5.1–5.11
    1. Cole S, Walsh A, Yin X, Wechalekar MD, Smith MD, Proudman SM, et al. .: Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 20: 85, 2018.
    1. Schuetz C, Hoenig M, Moshous D, Weinstock C, Castelle M, Bendavid M, et al. .: Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv 2: 2550–2553, 2018.
    1. Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, et al. .: Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med 383: 1149–1155, 2020.
    1. Clemens PL, Yan X, Lokhorst HM, Lonial S, Losic N, Khan I, et al. .: Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment. Clin Pharmacokinet 56: 915–924, 2017.
    1. Edwards RG, Vanderhoof S, Palestine A, Seibold LK: Bilateral secondary angle closure during daratumumab infusion: A case report and review of the literature. J Glaucoma 29: e83–e86, 2020.
    1. Lee AC, Greaves G, Lee R, Zdravkova M, Ahmad S, McGovern K, et al. .: Bilateral angle closure following the infusion of a monoclonal antibody to treat relapsing multiple myeloma. J Glaucoma 27: e145–e147, 2018.
    1. Khoo KM, Chang CF: Characterization and localization of CD38 in the vertebrate eye. Brain Res 821: 17–25, 1999.
    1. Mavrommatis MA, Jung H, Chari A, Barlogie B, Chelnis JG: Daratumumab-induced transient myopic shift. Am J Ophthalmol Case Rep 13: 116–118, 2018.
    1. Jokiranta TS, Solomon A, Pangburn MK, Zipfel PF, Meri S: Nephritogenic lambda light chain dimer: A unique human miniautoantibody against complement factor H. J Immunol 163: 4590–4596, 1999.
    1. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2: 1175–1178, 1986.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe